Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. METHODS: Using age-based sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Langer, C J, Hirsh, V, Okamoto, I, Lin, F-J, Wan, Y, Whiting, S, Ong, T J, Renschler, M F, Botteman, M F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647528/
https://www.ncbi.nlm.nih.gov/pubmed/26035702
http://dx.doi.org/10.1038/bjc.2015.181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647528/
https://www.ncbi.nlm.nih.gov/pubmed/26035702
http://dx.doi.org/10.1038/bjc.2015.181

Ejemplares similares